Stocktoria
Replimune Group, Inc. REPL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-07-20
Replimune Group, Inc. statistics & valuation
Market cap$960.3M
P / B2.3×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Return on assets | -44.9% | -44.2% | -27.0% | -25.6% | -14.9% |
| Return on equity | -59.5% | -57.6% | -31.4% | -28.7% | -16.2% |
| Debt / equity | 0.11× | 0.12× | 0.05× | 0.00× | — |
| Current ratio | 7.95 | 10.72 | 17.52 | 19.46 | 33.25 |
Source: SEC EDGAR filings · CIK 0001737953 · as of 2025-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.